Investment Rating - The investment rating for the company is "Buy" for both A and H shares [7]. Core Insights - The company reported a revenue of 6.67 billion RMB for 2025, representing a year-over-year increase of 14.9% (16.8% at constant exchange rates), and a net profit attributable to shareholders of 1.13 billion RMB, up 19.4% year-over-year [1][2]. - The company expects a revenue growth of 19%-22% for the full year of 2026, driven by a strong order backlog of 1.385 billion USD, which is a 31.7% increase year-over-year [1][5]. - Emerging businesses, particularly in chemical and biological macromolecules, have shown rapid growth, with revenues increasing by 57.3% year-over-year [3]. Summary by Sections Financial Performance - The company achieved a gross margin of 42.0% in 2025, a slight decrease of 0.4 percentage points year-over-year. The sales, management, and R&D expense ratios were 3.2%, 11.5%, and 8.9%, respectively, all showing a decrease year-over-year due to cost reduction initiatives [2]. - Operating cash flow for 2025 was 1.408 billion RMB, reflecting a 12.2% increase year-over-year, indicating improved cash flow levels [2]. Emerging Business Growth - Revenue from emerging businesses reached 1.929 billion RMB, with international revenue growing over 240%. The segment's gross margin improved to 30.1%, up 8.5 percentage points year-over-year [3]. - Specific highlights include: - Chemical macromolecules revenue of 1.028 billion RMB, up 123.7% year-over-year, with a significant increase in order backlog [3]. - Biological macromolecules revenue of 294 million RMB, up 95.8% year-over-year, with new production capacity expected to come online [3]. Core Business Development - The small molecule CDMO segment generated 4.735 billion RMB in revenue, a 3.6% increase year-over-year, with a total of 515 projects delivered [4]. - The company anticipates 16 small molecule PPQ projects in 2026, indicating a robust pipeline and commercial order reserves [4]. Profit Forecast and Valuation - The forecast for net profit attributable to shareholders for 2026-2028 is 1.42 billion, 1.84 billion, and 2.23 billion RMB, respectively, with adjustments reflecting a positive outlook on order levels and cost efficiency [5]. - The company is valued at 37x PE for A shares and 29x PE for H shares for 2026, with target prices set at 145.61 RMB and 129.44 HKD, respectively [5].

Investment Rating - The investment rating for the company is "Buy" for both A and H shares [7]. Core Views - The company reported a revenue of 6.67 billion RMB for 2025, representing a year-over-year increase of 14.9% (16.8% at constant exchange rates), and a net profit attributable to shareholders of 1.13 billion RMB, up 19.4% year-over-year [1][2]. - The company expects a revenue growth of 19%-22% for the full year of 2026, supported by a strong order backlog of 1.385 billion USD, which is a 31.7% increase year-over-year [1]. - Emerging businesses, particularly in chemical and biological macromolecules, have shown rapid growth, with a revenue increase of 57.3% year-over-year in 2025 [3]. Summary by Sections Financial Performance - The company achieved a gross margin of 42.0% in 2025, a slight decrease of 0.4 percentage points year-over-year. The sales, management, and R&D expense ratios were 3.2%, 11.5%, and 8.9%, respectively, all showing a decrease year-over-year due to cost reduction initiatives [2]. - Operating cash flow improved to 1.408 billion RMB, reflecting a 12.2% year-over-year increase [2]. Emerging Business Growth - Revenue from emerging businesses reached 1.929 billion RMB, with international revenue increasing by over 240%. The segment's gross margin improved to 30.1%, up 8.5 percentage points year-over-year [3]. - Specific highlights include: - Chemical macromolecules revenue of 1.028 billion RMB, up 123.7% year-over-year, with a significant order backlog growth of 127.6% [3]. - Biological macromolecules revenue of 294 million RMB, up 95.8% year-over-year, with a 55.6% increase in order backlog [3]. Core Business Development - The small molecule CDMO segment generated 4.735 billion RMB in revenue, a 3.6% year-over-year increase, with 515 projects delivered in 2025 [4]. - The company anticipates 16 small molecule PPQ projects in 2026, indicating a robust pipeline for future growth [4]. Profit Forecast and Valuation - The forecast for net profit attributable to shareholders for 2026-2028 is adjusted to 1.42 billion RMB, 1.84 billion RMB, and 2.23 billion RMB, respectively, with increases of 8% and 13% compared to previous estimates [5]. - The company is valued at 37x PE for A shares and 29x PE for H shares for 2026, with target prices set at 145.61 RMB and 129.44 HKD, respectively [5].

江苏扬农化工股份有限公司 2025 年年度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本公司根据上海证券交易所《上海证券交易所上市公司自律监管指引第 3 号——行业信息披露》《上市公司行业信息披露指引第十三号——化工》要求， 现将 2025 年年度主要经营数据披露如下： 二、主要产品和原材料的价格变动情况 （一）主要产品价格变动情况 证券代码：600486 证券简称：扬农化工 编号：临 2026-011 1 一、主要产品的产量、销量及收入实现情况 主要产品 产量（吨） 销量（吨） 营业收入（万元） 原药 113,776.72 113,475.18 731,528.72 制剂（不折百） 36,713.15 36,828.54 149,761.45 | | 2025 年度 | 2024 年度 | | | --- | --- | --- | --- | | | 平均采购价格 | 平均采购价格 | 价格变动情况 | | | （元/吨） | （元/吨） | | | 甲醛 | 1,061 | 1,087 | -2.4 ...

Investment Rating - The report assigns a "Buy" rating to the company, indicating a potential upside in the stock price [4]. Core Insights - The company has launched a stock incentive plan for its CDMO business core management and technical staff, which is expected to drive growth. The plan involves granting 7.597 million stock options at a price of 13.38 RMB, with performance targets set for net profit growth from 2026 to 2029 [4]. - The CDMO business has become the largest revenue contributor, with a revenue of 1.69 billion RMB in the first three quarters of 2025, representing a year-over-year growth of 20%. The gross margin for this segment is 44.5%, up by 3.7 percentage points [7]. - The company anticipates a recovery in overall performance, with expected net profits of 909 million RMB in 2025, 1.052 billion RMB in 2026, and 1.233 billion RMB in 2027, reflecting a year-over-year growth of 15.76% and 17.20% in the following years [6][7]. Financial Summary - The company’s projected net profit for 2025 is 909 million RMB, with an EPS of 0.78 RMB, and a P/E ratio of 22.91. For 2026, the net profit is expected to rise to 1.052 billion RMB, with an EPS of 0.91 RMB and a P/E ratio of 19.79. By 2027, the net profit is projected to reach 1.233 billion RMB, with an EPS of 1.06 RMB and a P/E ratio of 16.89 [6][10]. - The company’s revenue is expected to increase from 10.472 billion RMB in 2025 to 11.347 billion RMB in 2026, and further to 12.047 billion RMB in 2027 [10].

Investment Rating - The report upgrades the investment rating of the company to "Buy" [4] Core Insights - The company has launched a stock incentive plan for key management and technical personnel in its CDMO business, which is expected to drive growth. The plan involves granting 7.597 million stock options, representing approximately 0.66% of the total share capital, with a grant price of 13.38 RMB per share [4] - The CDMO business has become the largest revenue contributor, with a revenue of 1.69 billion RMB in the first three quarters of 2025, showing a year-over-year growth of 20%. The gross margin for this segment is 44.5%, an increase of 3.7 percentage points [7] - The company anticipates a recovery in performance, with projected net profits of 909 million RMB, 1.052 billion RMB, and 1.233 billion RMB for 2025, 2026, and 2027 respectively, reflecting a year-over-year growth of -11.9%, +15.8%, and +17.2% [6][7] Financial Summary - The company's projected net profit for 2025 is 909 million RMB, with an EPS of 0.78 RMB, and a P/E ratio of 22.91 [6] - For 2026, the net profit is expected to rise to 1.052 billion RMB, with an EPS of 0.91 RMB, and a P/E ratio of 19.79 [6] - By 2027, the net profit is projected to reach 1.233 billion RMB, with an EPS of 1.06 RMB, and a P/E ratio of 16.89 [6]

Core Viewpoint - The company reported significant growth in its financial performance for the year 2025, driven by increased demand in the peptide drug market, particularly in the areas of glucose-lowering and weight-loss medications [2][4]. Financial Data and Indicators - The company achieved an operating income of 741.34 million yuan, representing a year-on-year increase of 62.55% [2]. - The net profit attributable to the parent company was 165.82 million yuan, up 231.49% from the previous year [2]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was 172.65 million yuan, reflecting a growth of 278.52% [2]. Financial Condition - As of the end of 2025, the total assets of the company amounted to 1.937 billion yuan, an increase of 17.55% compared to the beginning of the reporting period [3]. - The equity attributable to the parent company was 1.065 billion yuan, which is a growth of 16.02% from the start of the period [3]. Factors Influencing Operating Performance - The company's focus on the synergistic development of its core business in peptide drug CDMO, raw materials, and formulations has led to a significant increase in sales of GLP-1 raw materials, contributing to the substantial improvement in operating performance [4]. - The increase in total operating income, operating profit, total profit, and net profit attributable to the parent company, as well as the basic earnings per share, was primarily due to the company's proactive expansion of its raw material market both domestically and internationally [5]. Changes Exceeding 30% - The company experienced significant changes exceeding 30% in various financial metrics, attributed to the successful implementation of new production capacity and increased sales of semaglutide and teriparatide raw materials [5]. - The company's share capital increased by more than 30% due to a capital reserve conversion, resulting in an increase in the number of shares from 112,418,556 to 157,385,978 [5].

Core Viewpoint - The company is planning to transfer 100% equity of its wholly-owned subsidiary, Hunan Sailong Biological Pharmaceutical Co., Ltd., through a public listing to optimize resource allocation and improve operational efficiency [2][5]. Group 1: Equity Transfer Details - The initial public listing for the transfer of Sailong Bio's 100% equity was held from January 23 to February 12, 2026, with a starting price set at RMB 86.95 million based on an assessment by Beijing Kunyuan Zhicheng Asset Appraisal Co., Ltd. [2] - Due to a lack of qualified buyers during the initial listing period, the company decided to reduce the listing price by 10% to RMB 78.255 million for the next round of public listing [2][3]. - If no qualified buyers are found after the next listing period, the company will apply for subsequent rounds of listing, with each round's price reduced by 10% from the previous [3]. Group 2: Financial Performance of Sailong Bio - Sailong Bio has been operating at a loss, reporting a loss of RMB 2.5186 million for the fiscal year 2024, which expanded to RMB 15.0288 million in the first three quarters of 2025 [4]. - Revenue for the first three quarters of 2025 was RMB 8.9229 million, while the total revenue for 2024 was RMB 10.9844 million [4]. - As of September 30, 2025, Sailong Bio's net assets were RMB 25.0493 million, down from RMB 40.077 million at the end of 2024 [4]. Group 3: Strategic Implications - The ongoing public listing of Sailong Bio's equity is aimed at optimizing the company's resource allocation, revitalizing assets, and enhancing operational efficiency, which aligns with the company's strategic development plan [5]. - The company emphasizes that the transaction will not harm the interests of shareholders, particularly minority shareholders, and the proceeds will be used for business development [5]. - The company retains the right to terminate the listing if no qualified buyers are found, and the final transaction price and counterparties will depend on the results of the public listing [3][5].

Core Viewpoint - The company Guangkang Biochemical announced a share reduction plan by specific shareholders, which may indicate a potential shift in investor sentiment and could impact the stock price in the near term [1][10]. Shareholder Reduction Plans - Specific shareholders, including Huatuo Zhiying No. 2, Huatuo Zhiyuan No. 3, and Ruihong Kaiyin No. 1, plan to reduce their holdings within three months from the announcement date through centralized bidding and block trading [1][4]. - Huatuo Zhiying No. 2 and Huatuo Zhiyuan No. 3 plan to collectively reduce up to 1.3198 million shares, accounting for 1.7835% of the total share capital, while Ruihong Kaiyin No. 1 plans to reduce up to 1.98 million shares, representing 2.6757% of the total share capital [4][6]. Historical Context of Share Reductions - The shareholders are preparing for a "clearance-style" reduction, with Ruihong Kaiyin No. 1 having previously announced a similar reduction plan in October 2025, which was not executed [7]. - Huatuo Zhiying No. 2 and Huatuo Zhiyuan No. 3 had also announced a reduction plan in September 2025, resulting in a decrease in Huatuo Zhiyuan No. 3's holding from 0.6022% to 0.5884% [7]. Company Background - Guangkang Biochemical is a national high-tech enterprise specializing in the research, production, and sales of pesticide active ingredients, intermediates, and formulations [8]. - The company received a warning letter from the Guangdong Securities Regulatory Bureau a month prior to the announcement of the share reduction [10]. Financial Management Issues - From July 2023 to August 2025, the company used raised funds for cash management, purchasing 179 financial products, of which 158 were non-principal guaranteed products. The company did not adequately disclose the risks associated with these investments in its reports [10]. Stock Performance - The timing of the reduction announcement coincides with a nearly 20% rebound in the company's stock price from February 6 to February 11. Following the announcement, the stock initially dipped but later rebounded, closing up over 5% [10].

Group 1: R&D and Client Collaboration - The company focuses on serving large multinational pharmaceutical companies and original research drug companies, aiming to provide raw materials for 8 original drug varieties and plans to add 1-2 new commercialized raw materials annually [2] - Established long-term strategic partnerships with renowned pharmaceutical companies such as Novartis and Sanofi, expanding collaboration from sartan raw materials to non-sartan raw materials, patent-expired drugs, and innovative drug projects [2] Group 2: CDMO Business Strategy - The company has built a solid service foundation and professional competitiveness in the generic drug raw material field, leveraging a comprehensive GMP system and compliance capabilities [3] - The CDMO business focuses on strategic clients, prioritizing high-potential projects during patent periods and late-stage development, ensuring significant scale benefits and customer loyalty [3] Group 3: Business Growth Outlook for 2026 - Raw material segment: Sartan raw materials' revenue share is expected to decline, while non-sartan raw materials (e.g., sitagliptin, ezetimibe) are projected to be core growth drivers, maintaining rapid growth and potential margin improvement [4] - CDMO business: Revenue may face pressure due to changing client demands, but the company is actively pursuing new project opportunities to maintain stability [4] - Formulation business: Expected to continue rapid growth due to expanding market channels, despite a small revenue base [4] - Acetonitrile project: The annual production capacity of 20,000 tons has passed acceptance in January 2026, targeting high-end fields such as peptides and small nucleic acids [4] Group 4: Profitability and Cost Management - Sartan raw materials maintain a gross margin above 30% despite competitive pricing pressures, with expectations for stable margins as prices stabilize [5] - Non-sartan raw materials' gross margin is expected to improve as production increases and costs decrease, aiming to align closer to sartan products [5] Group 5: R&D and Sales Expenses - The company's overall R&D investment will remain stable at approximately 2.5-2.8 billion annually, with a rising proportion allocated to raw materials and CDMO R&D [5] - Sales expenses are increasing rapidly in the formulation business due to its growth, with the company enhancing marketing control through digital systems [5]

Group 1 - The article highlights the transformation of the Sanfang Industrial Park in Haimen District, Nantong City, from a historical industrial hub to a modern industrial highland, driven by innovation and industry [1] - Zhongxing Energy, a leading company in the steel pipe industry, has significantly improved its production efficiency with a fully automated acid washing line, increasing its annual capacity to 70,000 tons while reducing labor needs to just 8 workers [1] - The intelligent logistics warehouse of Weibosite has enhanced order response times for major brands like Uniqlo and ZARA through a digital twin technology-integrated storage system, promoting standardization and high-end development in the fabric industry [1] Group 2 - In the life and health sector, Jiangsu Huiju Pharmaceutical, recognized as a "little giant" enterprise, leads the industry with an integrated strategy of raw materials and formulations, serving over 300 global clients [2] - The new materials industry is experiencing robust growth, with companies like Ronghui Lithium and Xinwei Nickel Cobalt driving the development of lithium battery materials and optical communication technologies, creating a comprehensive industrial ecosystem [2] - The Sanfang Industrial Park reported an industrial output value of 3.812 billion yuan in the first half of 2025, reflecting a year-on-year growth of 13.37%, alongside a 42% increase in general public budget revenue [2] Group 3 - The park is leveraging national strategies such as the Yangtze River Economic Belt to cultivate a cluster of technology-driven enterprises, positioning itself as a benchmark for industrial transformation and innovation in the region [3] - The park's leadership emphasizes the importance of a supportive business environment, aiming to attract high-end resources and facilitate the transformation of research achievements into practical applications [3] - The revitalization of the Qinglong Port area combines historical industrial heritage with modern innovation, enhancing tourism value and benefiting from improved transportation links to Shanghai [3]